Clinical Trial Update: Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease [Phase 3]

View source ↗

Summary

Phase 3 open-label trial assessing efficacy and safety of Anti-MAP therapy in adults with Crohn's disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Anti-MAP therapy

Snippet

Sponsor: RedHill Biopharma Limited | Conditions: Crohn Disease | Phase 3 | Status: COMPLETED | Results posted: 2021-02-24